Expert Ratings for Accolade
Within the last quarter, Accolade (NASDAQ:ACCD) has observed the following analyst ratings:
Wells Fargo Initiates Coverage On Accolade with Underweight Rating, Announces Price Target of $9
Wells Fargo analyst Stan Berenshteyn initiates coverage on Accolade (NASDAQ:ACCD) with a Underweight rating and announces Price Target of $9.
What 5 Analyst Ratings Have To Say About Accolade
Accolade (NASDAQ:ACCD) has observed the following analyst ratings within the last quarter:
Analyst Ratings For Accolade
Over the past 3 months, 5 analysts have published their opinion on Accolade (NASDAQ:ACCD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Goldman Sachs Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $32
Goldman Sachs analyst Cindy Motz initiates coverage on Accolade (NASDAQ:ACCD) with a Buy rating and announces Price Target of $32.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Enveric Biosciences (NASDAQ:ENVB) stock rose 6.8% to $0.64 during Friday's after-market session. The market value of their outstanding shares is at $20.8 million.
48 Biggest Movers From Yesterday
Gainers
Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT performance drink in Walmart stores across Florida metropolitan areas.